Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038220 (
status epilepticus
)
7,272
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Up to this day, the roles of
PEA15
expression and its phosphorylation in seizure-related events have not been still unclear. In the present study, we found that
PEA15
was distinctly phosphorylated in reactive astrocytes and apoptotic astrocytes in the rat hippocampus following LiCl-pilocarpine-induced
status epilepticus
(SE, a prolonged seizure activity).
PEA15
-serine (S) 104 phosphorylation was up-regulated in reactive astrocytes following SE, although
PEA15
expression and its S116 phosphorylation were unaltered. Bisindolylmaleimide (BIM), a protein kinase C (PKC) inhibitor, attenuated SE-induced reactive astrogliosis, but phorbol 12-myristate 13-acetate (PMA, a PKC activator) aggravated it. Unlike reactive astrocytes,
PEA15
-S116 phosphorylation was reduced in apoptotic astrocytes. However,
PEA15
expression and its S104 phosphorylation were unchanged in apoptotic astrocyte. Neither BIM nor PMA affected SE-induced astroglial apoptosis.
PEA15
expression and its phosphorylations were not relevant to SE-induced CA1 neuronal death. These findings indicate that
PEA15
-S104 and S116 phosphorylations may play a role in reactive astrogliosis and prevention of astroglial apoptosis, respectively. Therefore, we suggest that the selective manipulation of
PEA15
phosphorylations may regulate apoptotic and/or proliferative signals in astrocytes.
...
PMID:The differential roles of PEA15 phosphorylations in reactive astrogliosis and astroglial apoptosis following status epilepticus. 2943 77